Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company is headquartered in Kennesaw, Georgia and currently employs 1,600 full-time employees. The firm is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.
Follow-Up Questions
Artivion Inc의 CEO는 누구입니까?
Mr. James Mackin은 2014부터 회사에 합류한 Artivion Inc의 Chairman of the Board입니다.
AORT 주식의 가격 성능은 어떻습니까?
AORT의 현재 가격은 $40.93이며, 전 거래일에 decreased 1.02% 하였습니다.
Artivion Inc의 주요 사업 주제나 업종은 무엇입니까?
Artivion Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Artivion Inc의 시가총액은 얼마입니까?
Artivion Inc의 현재 시가총액은 $1.9B입니다
Artivion Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 9명의 분석가가 Artivion Inc에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 7명의 매수, 2명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다